18 F]FDG-PET revealed pathological findings in 18 of 26 patients. Three scans were categorised as grade I, 12 as grade II and 3 as grade III arteritis. Visual grade was significantly correlated with both CRP and ESR levels (p=0.002 and 0.007 respectively; grade I: CRP 4.0 mg/l, ESR 6 mm/h; grade II: CRP 37 mg/l, ESR 46 mm/h; grade III: CRP 172 mg/l, ESR 90 mm/h). Overall sensitivity was 60% (95% CI 40.6-77.3%), specificity 99.8% (95% CI 89.1-100%), positive predictive value 99.7% (95% CI 77-100%), negative predictive value 67.9% (95% CI 49.8-80.9%) and accuracy 78.6% (95% CI 65.6-88.4%). In patients presenting with a CRP <12 mg/l or an ESR <12 mm/h, logistic regression revealed a sensitivity of less than 50%. In patients with high CRP/ESR levels, sensitivity was 95.5%/80.7%.
Introduction
The diagnosis of large-vessel vasculitis and the assessment of its activity and extent remain challenging, especially in patients presenting with a constellation of non-specific symptoms and laboratory tests. The standard diagnostic procedures include biopsy, angiography, ultrasound and magnetic resonance angiography (MRA); nevertheless, these procedures are invasive, are largely operator-dependent or document only morphological changes, such as stenosis, occlusion and aneurysmal transformation, which mainly occur in late stages of the disease [1] [2] [3] [4] [5] .
Positron emission tomography (PET) is an operatorindependent, non-invasive metabolic imaging modality based on the regional distribution of 18 F-fluorodeoxyglucose ([ 18 F]FDG) which plays a major role in the management of oncology patients. However, activated inflammatory cells have also been shown to overexpress glucose transporters and to accumulate increased amounts of glucose and structurally related substances such as [ 18 F]FDG [6, 7] ; therefore, [ 18 F]FDG-PET may become a useful tool in the evaluation of Takayasu's arteritis (TA) and giant cell arteritis (GCA). Nevertheless, the lack of accurate criteria for vasculitis imaging based on [ 18 F]FDG-PET has restricted its use so far. This study therefore aimed to explore the properties of [ 18 F]FDG-PET in the detection of large-vessel vasculitis and in the assessment of the activity and extent of disease.
Materials and methods

Patients
Throughout a period of 24 months (from April 2002 to April 2004), 26 consecutive patients (21 females, 5 males; median age 71 years, range 17-86 years) with a clinical diagnosis of GCA (20 patients) or TA (six patients) were examined with [ 18 F]FDG-PET. Follow-up scans were performed in four patients. Twenty-one of the 30 scans (70%) were performed under simultaneous glucocorticosteroid treatment. The classification as GCA or TA was made according to the ACR classification criteria [8, 9] and verified when at least three of the criteria were present. Patients were referred by the Department of Rheumatology of the University Medical Centre. Patient characteristics and baseline investigation results are shown in Table 1 ]FDG with the patient in the supine position. We performed whole-body scans using 2D acquisition with 12-14 contiguous bed positions (8 min/bed position: 6-min emission scan and 2-min attenuation correction with a rotating 68 Ge line sources). Iterative reconstruction of the transaxial slices was performed using the ordered subset-expectation maximisation (OS-EM) algorithm (two iterations, eight subsets).
Evaluation and scoring of data
Images were judged by two experienced nuclear medicine physicians blinded to the clinical and laboratory data. At a time interval of 1 month, the same two observers evaluated the same images blinded to the previous judgment. The severity of large-vessel [ 18 F]FDG uptake was visually graded using a four-point scale (Fig. 1a) : 0, no uptake present; I, low-grade uptake (uptake present but lower than liver uptake); II, intermediate-grade uptake (similar to liver uptake); III, high-grade uptake (uptake higher than liver uptake).
Statistical evaluation
All data are expressed as median (range) in text and tables. To ascertain whether CRP and ESR levels were positively associated with the grade of [ 18 F]FDG uptake, the Jonckheere-Terpstra test was used. Logistic regression was used to assess the effects of CRP and ESR on the sensitivity of [
18 F]FDG-PET. Statistical significance was defined as p<0.05. Data were analysed using Statistica Version 6.0 for Windows (StatSoft Inc., Tulsa, USA).
Results
Reference group
Grade I [ F]FDG uptake in the abdominal part of the descending aorta or in one of the large aortic branches was not found in any of the control group, nor were there any instances of grade II or III uptake in controls. Therefore, in the present study, grade II or III uptake in the thoracic aorta and any visible uptake in other segments was considered as pathological and due to active arterial inflammation.
Assessment of activity
Thirty PET scans were performed (26 baseline and 4 follow-up studies) in the patients. Three scans were judged as grade I, 12 as grade II and 3 as grade III arteritis. Inter- Follow-up PET studies were performed in four patients. All of them had received glucocorticosteroid drug treat- (Fig. 3) . Separate analysis in those with a high ESR revealed a sensitivity of 78.6% for patients suffering from GCA (22 scans) and 40.3% for patients suffering from TA (eight scans).
Compared with ESR, CRP showed a superior correlation with the sensitivity of [
18 F]FDG-PET. For patients presenting with a CRP <12 mg/l, logistic regression revealed [
18 F]FDG-PET to have a sensitivity of less than 50%. With high CRP levels, sensitivity increased to 95.5% (Fig. 3) . Separate analysis revealed a sensitivity of 93.7% for patients suffering from GCA (22 scans) and 46.6% for patients suffering from TA (eight scans), at high CRP levels.
Ten of 21 PET scans (47.6%) with and eight of nine scans (88.9%) without simultaneous glucocorticosteroid treatment showed pathological large-vessel [ 
Assessment of disease extent
The extent of large-vessel vasculitis was assessed using MRA, ultrasound, temporal artery biopsy or aortic biopsy prior to [ [10] . In addition, the use of [ 18 F]FDG-PET in GCA or TA has recently been suggested by numerous case reports [11] [12] [13] [14] [15] [16] [17] [18] and observations in a limited number of patients [19, 20] . Larger studies, however, are few in number and have not yet conclusively verified the relation between [ 18 F]FDG uptake and severity of GCA and TA. In 25 patients with either GCA or polymyalgia rheumatica, no significant correlation was found between [
18 F] FDG-PET results and inflammatory markers [21] . In a further study, 18 patients with TA were classified into [
18 F] FDG-PET-positive and -negative groups; the [ 18 F]FDG-PET-positive patients showed significantly higher CRP and ESR levels than those with a negative scan [22] .
In the present study we used a four-point scale (Fig. 1a ) to grade the large-vessel [
18 F]FDG uptake into none (grade 0), lower than liver uptake (grade I), similar to liver uptake (grade II) and higher than liver uptake (grade III). This scale was proposed by Meller et al. [23] , who reported no association with their patients' clinical or biochemical data. In contrast, we found a highly significant correlation between visual score and both CRP and ESR (Fig. 2) ; hence, this study is the first report to validate the visual arteritis score. With the use of this score, high inter-observer agreement and very good intra-observer reproducibility were achieved.
Nevertheless, the major advantage of the visual arteritis score is the achievement of high specificity for active largevessel inflammation by excluding [ 18 F]FDG accumulation due to active atherosclerosis. Atherosclerotic plaques also accumulate glucose analogues [24] and modest large-vessel [ 18 F]FDG accumulation consequently occurs at the level of the major vessels in about 50% of all PET scans [25, 26] . Accordingly, in our control group grade I vessel uptake was frequently found in the thoracic part of the aorta. Thus, only grade II or III uptake in the thoracic aorta and any visible uptake in other segments should be judged to represent active large-vessel inflammation. [22] . Our results offer an explanation for these discrepant findings.
With an overall sensitivity of 60%, we were able to show that the sensitivity strongly depends on the present severity of inflammation as assessed by the CRP or ESR levels (Fig. 3) . Compared with ESR, CRP is a better predictor of the sensitivity of [ 18 F]FDG-PET, and a 95.5% sensitivity can be achieved at high CRP levels. However, several authors have previously reported that, unlike inflammatory markers of GCA, those of TA do not always reflect the inflammatory activity of the disease [27] . This is also reflected by our finding of a better correlation between biochemical inflammatory markers and the sensitivity of [ Extracranial involvement is commonly asymptomatic and most often discovered only after serious complications such as strokes, myocardial infarction, ruptured aortic aneurysm or aortic dissection. [28] [29] [30] [31] . However, the standard diagnostic modalities such as biopsy, angiography, ultrasound and MRA are commonly unable to demonstrate the full extent of vascular involvement in large-vessel arteritis [1] [2] [3] [4] [5] . In contrast, [ 18 F]FDG-PET offers the possibility of demonstrating the overall topography of largevessel involvement as it can visually represent the whole body in a single image (Figs. 1b, c, 4, 5) . In this study, [ 18 F] FDG-PET confirmed the previous diagnosis in 18 of 26 patients and found unexpected extensive involvement in eight patients. These results are comparable to prior findings and highlight the major advantage of [ 18 F]FDG-PET in the work-up of patients with large-vessel vasculitis [11, 22, 23, 32, 33] . The assessment of extent, however, is limited to extracranial vessels, as the elevated physiological glucose metabolism in the brain obscures [ process and its distribution. The main application will be in the evaluation of atypical presentations of large-vessel vasculitis and in the monitoring of response to anti-inflammatory treatment and disease recurrence. [ 18 F]FDG-PET is of potential value in reducing the time to diagnosis (by guiding the selection of the site of choice for a diagnostic biopsy) and in limiting the number of angiograms performed on a patient once the diagnosis has been established. Prospective intervention studies, however, will be helpful in order to further clarify the role of [
18 F]FDG-PET in large-vessel inflammation.
In conclusion, [
18 F]FDG-PET is highly effective in assessing the activity and the extent of large-vessel vasculitis. A visual grading scale was validated as representing the severity of inflammation. Its use is simple and it provides high specificity, while high sensitivity is achieved by PET scanning during the active inflammatory phase.
